Breakthrough in Pediatric Brain Cancer Treatment: Virginia Tech Researchers Seek Precision and Effectiveness

Strategic Insights -

Virginia Tech researchers are making a significant stride in treating pediatric brain cancer, specifically glioblastoma, by developing novel therapies that target cancer cells while sparing healthy tissue. With the support of The Children's Cancer Foundation Inc., the team, led by Kathleen Mulvaney, aims to create more precise and effective treatments for children with this devastating disease. The researchers are focusing on a protein called KAT6A, which plays a crucial role in cancer-driving pathways, and are exploring new methods to deliver therapeutics to brain tumors using low-intensity focused ultrasound.

Key Takeaways:

  • The Virginia Tech research team is developing novel therapies for pediatric glioblastoma, targeting cancer cells while sparing healthy tissue.
  • Kathleen Mulvaney, a cancer biologist, is leading the research effort, which is supported by The Children's Cancer Foundation Inc.
  • The team is focusing on a protein called KAT6A, which plays a key role in cancer-driving pathways.
  • Experimental compounds, such as Pf9363, selectively target KAT6A and may provide more effective treatment options for pediatric glioblastoma.
  • The researchers plan to use low-intensity focused ultrasound to deliver therapeutics through the blood-brain barrier, temporarily opening it to allow for more effective tumor targeting.
  • The one-year study aims to provide better treatments for nearly half of children with glioblastoma and may lead to future clinical trials combining multiple therapies.

Statistics:

  • Nearly half of children with glioblastoma may benefit from the new treatments developed by the Virginia Tech research team.
  • The study is focused on glioblastoma, an aggressive brain cancer that affects children and has limited treatment options.
  • The research team is exploring new methods to deliver therapeutics to brain tumors using low-intensity focused ultrasound.
  • The study will test a compound called Pf9363 as a potential treatment for pediatric glioblastoma.

Sources:

  • NewsRx LLC, 2025 JUN 21, Pediatrics Week
  • The Children's Cancer Foundation Inc. (CCF), grant support for the research
  • Fralin Biomedical Research Institute Cancer Research Center, Washington, D.C., home of Kathleen Mulvaney's research team.